吉非替尼联合培美曲塞靶向治疗晚期非小细胞肺癌的疗效及预后  

Efficacy and prognosis of gefitinib combined with pemetrexed targeted therapy for advanced non-small cell lung cancer

作　　者：吴倩 柴晓菲[2] 方学辉 韩雪梅 WU Qian;CHAI Xiaofei;FANG Xuehui;HAN Xuemei(Department of Medical Oncology,Luoyang Dongfang People’s Hospital,Luoyang 471003,He’nan,China;Department of Pathology,He’nan Cancer Hospital,Zhengzhou 450000,He’nan,China)

机构地区：[1]洛阳市东方人民医院肿瘤内科,河南洛阳471003 [2]河南省肿瘤医院病理科,郑州450000

出　　处：《癌症进展》2023年第10期1148-1150,1154,共4页Oncology Progress

摘　　要：目的探讨吉非替尼联合培美曲塞靶向治疗晚期非小细胞肺癌(NSCLC)的疗效及预后。方法依据化疗方案的不同将82例NSCLC患者分为观察组(n=42)和对照组(n=40),对照组患者给予培美曲塞+顺铂化疗,观察者患者给予吉非替尼联合培美曲塞+顺铂治疗。比较两组患者的临床疗效、肿瘤标志物[血管内皮生长因子(VEGF)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)]水平、不良反应发生情况及生存情况。结果观察组患者的客观缓解率为85.71%,高于对照组患者的65.00%(P﹤0.05);观察组患者的疾病控制率为95.24%,高于对照组患者的80.00%(P﹤0.05)。治疗后,两组患者CEA、VEGF、CYFRA21-1水平均低于本组治疗前,且观察组患者CEA、VEGF、CYFRA21-1水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为16.67%,与对照组患者的22.50%比较,差异无统计学意义(P﹥0.05)。观察组患者的1年生存率为61.90%,与对照组患者的45.00%比较,差异无统计学意义(P﹥0.05)。结论吉非替尼联合培美曲塞靶向治疗晚期NSCLC患者,能够有效提高临床疗效,控制疾病进展,降低肿瘤标志物水平,安全性较高。Objective To investigate the efficacy and prognosis of gefitinib combined with pemetrexed targeted therapy for advanced non-small cell lung cancer(NSCLC).Method A total of 82 NSCLC patients were divided into observation group(n=42)and control group(n=40)according to different chemotherapy regimens.Patients in the control group were treated with pemetrexed+cisplatin chemotherapy,and patients in the observation group were treated with gefitinib combined with pemetrexed+cisplatin.The clinical efficacy,tumor markers[vascular endothelial growth factor(VEGF),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)]levels,adverse events,and survival were compared between the two groups.Result The objective response rate of the observation group was 85.71%,which was higher than 65.00% of the control group,the difference was statistically significant(P<0.05).The disease control rate of the observation group was 95.24%,which was higher than 80.00% of the control group,the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,VEGF,and CYFRA21-1 in the two groups were lower than those before the treatment,and the levels of the above indicators in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse events in the observation group was 16.67%,compared with 22.50% in the control group,the difference was not statistically significant(P>0.05).The one year survival rate of the observation group patients was 61.90%,which was not statistically significant compared to 45.00% of the control group(P>0.05).Conclusion Gefitinib combined with pemetrexed targeted therapy for advanced NSCLC patients can effectively improve clinical efficacy,control disease progression,reduce the levels of tumor markers,and has high safety.

关 键 词：非小细胞肺癌 吉非替尼 培美曲塞 疗效 

分 类 号：R734.2[医药卫生—肿瘤]